Procalcitonin and CRP were equally useful in children infected and not infected with HIV to improve the specificity of the pneumococcal pneumonia efficacy endpoint in the vaccine trial among children with CXR-confirmed pneumonia. The gene discussed is CRP; the disease is susceptibility to pneumonia measurement.